NOVOCURE LTD's ticker is NVCR and the CUSIP is G6674U108. A total of 264 filers reported holding NOVOCURE LTD in Q2 2020. The put-call ratio across all filers is 1.62 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $20,318,557 | -62.7% | 1,258,115 | -4.1% | 0.04% | -65.0% |
| Q2 2023 | $54,439,949 | +114.0% | 1,311,806 | +210.1% | 0.12% | +87.5% |
| Q1 2023 | $25,440,965 | +1438.1% | 423,029 | +1677.4% | 0.06% | +1180.0% |
| Q2 2022 | $1,654,000 | -67.5% | 23,800 | -61.2% | 0.01% | -68.8% |
| Q1 2022 | $5,087,000 | -10.8% | 61,393 | -19.2% | 0.02% | -20.0% |
| Q4 2021 | $5,704,000 | +425.2% | 75,966 | +712.3% | 0.02% | +300.0% |
| Q3 2021 | $1,086,000 | -87.9% | 9,352 | -88.4% | 0.01% | -92.4% |
| Q3 2020 | $8,970,000 | -58.1% | 80,588 | -77.7% | 0.07% | -64.5% |
| Q2 2020 | $21,411,000 | +1572.7% | 361,055 | +1684.2% | 0.19% | +2225.0% |
| Q2 2019 | $1,280,000 | +140.6% | 20,236 | +83.2% | 0.01% | +100.0% |
| Q1 2019 | $532,000 | +10.8% | 11,047 | +20.5% | 0.00% | +100.0% |
| Q3 2018 | $480,000 | -24.2% | 9,165 | -68.4% | 0.00% | -33.3% |
| Q1 2018 | $633,000 | – | 29,036 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Invus Financial Advisors, LLC | 350,884 | $77,833,000 | 15.51% |
| HARTLINE INVESTMENT CORP/ | 302,194 | $67,033,000 | 8.47% |
| Darsana Capital Partners LP | 700,000 | $155,274,000 | 4.42% |
| MORGAN JESS S & CO INC | 23,775 | $5,274,000 | 3.47% |
| Soleus Capital Management, L.P. | 98,975 | $21,955,000 | 3.38% |
| Montanaro Asset Management Ltd | 116,650 | $25,875,000 | 3.26% |
| Taylor Frigon Capital Management LLC | 31,035 | $6,884,000 | 2.15% |
| Rhenman & Partners Asset Management AB | 120,000 | $26,618,000 | 1.81% |
| COURAGE CAPITAL MANAGEMENT LLC | 10,000 | $2,218,000 | 1.33% |
| Derbend Asset Management | 5,789 | $1,284,000 | 1.20% |